Ensho Therapeutics is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company launched with the announcement of acquiring a portfolio of oral α4β7 integrin inhibitors through a worldwide exclusive license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. Ensho has the right to develop, manufacture, and commercialize these assets globally, excluding certain Asian jurisdictions.